These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2162294)

  • 21. Kinetics and dynamics of enalapril in patients with liver cirrhosis.
    Ohnishi A; Tsuboi Y; Ishizaki T; Kubota K; Ohno T; Yoshida H; Kanezaki A; Tanaka T
    Clin Pharmacol Ther; 1989 Jun; 45(6):657-65. PubMed ID: 2543535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical pharmacology of enalapril.
    Gomez HJ; Cirillo VJ; Jones KH
    J Hypertens Suppl; 1983 Oct; 1(1):65-70. PubMed ID: 6100610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intracoronary blockade of angiotensin-converting enzyme in humans: interaction with cardiac sympathetic neurotransmission?
    Rundqvist B; Eisenhofer G; Emanuelsson H; Albertsson P; Friberg P
    Acta Physiol Scand; 1997 Sep; 161(1):15-22. PubMed ID: 9381945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute haemodynamic, hormonal and electrolyte effects and short-term clinical response to enalapril in heart failure.
    Fitzpatrick D; Nicholls MG; Ikram H; Espiner EA
    J Hypertens Suppl; 1983 Oct; 1(1):147-53. PubMed ID: 6100604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays.
    Arafat T; Awad R; Hamad M; Azzam R; Al-Nasan A; Jehanli A; Matalka K
    J Clin Pharm Ther; 2005 Aug; 30(4):319-28. PubMed ID: 15985045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Both enalapril and losartan attenuate sarcolemmal Na+-K+-ATPase remodeling in failing rat heart due to myocardial infarction.
    Guo X; Wang J; Elimban V; Dhalla NS
    Can J Physiol Pharmacol; 2008 Apr; 86(4):139-47. PubMed ID: 18418421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of congestive heart failure: experience with fosinopril.
    Blumenthal M
    Am J Hypertens; 1997 Oct; 10(10 Pt 2):289S-298S. PubMed ID: 9366286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of enalapril in congestive heart failure.
    Dickstein K
    Drugs; 1986; 32 Suppl 5():40-4. PubMed ID: 3032562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enalapril: a review of human pharmacology.
    Gomez HJ; Cirillo VJ; Irvin JD
    Drugs; 1985; 30 Suppl 1():13-24. PubMed ID: 2994984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in beta-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system.
    Sethi R; Shao Q; Ren B; Saini HK; Takeda N; Dhalla NS
    Mol Cell Biochem; 2004 Aug; 263(1-2):11-20. PubMed ID: 15524163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.
    Plosker GL; Sorkin EM
    Drugs; 1994 Aug; 48(2):227-52. PubMed ID: 7527326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of enalapril on myocardial noradrenaline overflow during exercise in patients with chronic heart failure.
    Mulligan IP; Fraser AG; Lewis MJ; Henderson AH
    Br Heart J; 1989 Jan; 61(1):23-8. PubMed ID: 2537095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormonal, blood pressure, and peritoneal transport response to short-term ACE inhibition.
    Ripley EB; Gehr TW; Kish CW; Sica DA
    Perit Dial Int; 1994; 14(4):378-83. PubMed ID: 7827189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure.
    Webster MW; Fitzpatrick MA; Hamilton EJ; Nicholls MG; Ikram H; Espiner EA; Wells JE
    Drugs; 1985; 30 Suppl 1():74-81. PubMed ID: 2994990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of cardiac failure with enalapril].
    Bounhoure JP
    Presse Med; 1985 Dec; 14(44):2215-7. PubMed ID: 3003728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of angiotensin-converting enzyme inhibitors in congestive heart failure.
    Galvao M
    Heart Lung; 1990 Sep; 19(5 Pt 1):505-11. PubMed ID: 2211159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocrine mechanisms in congestive cardiac failure. Renin, aldosterone and atrial natriuretic hormone.
    Laragh JH
    Drugs; 1986; 32 Suppl 5():1-12. PubMed ID: 2952486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal and adrenal resistance against atrial natriuretic peptide in congestive heart failure: effect of angiotensin I-converting-enzyme inhibition.
    Wambach G; Schittenhelm U; Bönner G; Kaufmann W
    Cardiology; 1989; 76(6):418-27. PubMed ID: 2558792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy.
    Abrams WB; Davies RO; Ferguson RK
    Fed Proc; 1984 Apr; 43(5):1314-21. PubMed ID: 6323221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.